Stock Events

Stock Events

Candel Therapeutics 

$4.93
0
+$0+0% Today

Statistics

Day High
4.94
Day Low
4.83
52W High
-
52W Low
-
Volume
2,157
Avg. Volume
-
Mkt Cap
270.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.54
-0.42
-0.3
-0.19
Expected EPS
-0.305149
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-110.35MNet Income

Analyst Ratings

$20.50Average Price Target
The highest estimate is 26.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CADL.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Marker Therapeutics
MRKR
Mkt Cap12.78M
Marker Therapeutics, Inc. is involved in the development of novel cell-based immunotherapies for cancer, presenting a direct competition to Candel's gene therapy and immunotherapy approaches.
Nkarta
NKTX
Mkt Cap149.86M
Nkarta, Inc. focuses on the engineering and development of natural killer cell therapies for cancer, offering an alternative approach to Candel's viral vector-based therapies.
Precigen
PGEN
Mkt Cap1.46B
Precigen, Inc. is a biotechnology company that develops gene and cell therapies, including for oncology, which competes with Candel's gene therapy approaches.
Iovance Biotherapeutics
IOVA
Mkt Cap712.85M
Iovance Biotherapeutics, Inc. specializes in tumor-infiltrating lymphocyte (TIL) therapies for cancer, offering a competitive approach to Candel's immunotherapy strategies.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG is focused on developing gene-based medicines, including for cancer, which competes with Candel's gene therapy platform.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE is engaged in developing individualized cancer therapies, including mRNA-based vaccines, competing with Candel's viral vector and immunotherapy approaches.

About

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Show more...
CEO
ISIN
US1374041093

Listings

BOATS
BOATS
CADL.BOATS
XNAS
US
CADL

0 Comments

Share your thoughts

FAQ

What is Candel Therapeutics stock price today?▼
The current price of CADL.BOATS is $4.93 USD — it has increased by +0% in the past 24 hours. Watch Candel Therapeutics stock price performance more closely on the chart.
What is Candel Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Candel Therapeutics stocks are traded under the ticker CADL.BOATS.
What is Candel Therapeutics market cap?▼
Today Candel Therapeutics has the market capitalization of 270.65M
When is the next Candel Therapeutics earnings date?▼
Candel Therapeutics is going to release the next earnings report on May 07, 2026.
What were Candel Therapeutics earnings last quarter?▼
CADL.BOATS earnings for the last quarter are -0.54 USD per share, whereas the estimation was -0.24 USD resulting in a -120.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Candel Therapeutics revenue for the last year?▼
Candel Therapeutics revenue for the last year amounts to 0 USD.
What is Candel Therapeutics net income for the last year?▼
CADL.BOATS net income for the last year is -110.35M USD.
When did Candel Therapeutics complete a stock split?▼
Candel Therapeutics has not had any recent stock splits.